Trials / Not Yet Recruiting
Not Yet RecruitingNCT07418879
A Real-world Study of Pralsetinib Combined With Leucogen in the Treatment of RET Fusion-positive NSCLC
A Real-world Clinical Study of Pralsetinib in the Treatment of RET Fusion-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Prophylactic Use of Leukocyte-increasing Drug Leucogen
- Status
- Not Yet Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- Sponsor
- Fudan University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a single-arm, multicenter real-world clinical study designed to evaluate the safety and efficacy of Leucogen (a leukocyte-increasing agent) as a prophylactic treatment in patients with RET fusion-positive non-small cell lung cancer (NSCLC) who are being treated with Pralsetinib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pralsetinib | Pralsetinib 400mg orally once daily on an empty stomach (4 weeks as a cycle, until disease progression, death, or intolerance) |
| DRUG | Leucogen | Leucogen 20mg orally three times daily for continuous prophylactic treatment for 3 months |
Timeline
- Start date
- 2026-02-05
- Primary completion
- 2027-12-31
- Completion
- 2028-12-31
- First posted
- 2026-02-18
- Last updated
- 2026-02-18
Source: ClinicalTrials.gov record NCT07418879. Inclusion in this directory is not an endorsement.